Recruitment methods for united states alzheimer disease prevention trials

Journal of Nutrition, Health and Aging

Volumn 16, Issue 4, 2012, Pages 331-335

  Schneider, L S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Clinical trials; Methods; Mild cognitive impairment; Prevention; Recruitment; Trials

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; CELECOXIB; ESTROGEN; NAPROXEN; SELENIUM; SIMVASTATIN; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DEMENTIA; DISEASE COURSE; DISEASE MARKER; DISEASE REGISTRY; DRUG EFFICACY; FOLLOW UP; GINKGO BILOBA; HEALTH INSURANCE; HEART INFARCTION; HEART PROTECTION; HUMAN; MEDICARE; MILD COGNITIVE IMPAIRMENT; NEUROPATHOLOGY; NEUROPHYSIOLOGICAL RECRUITMENT; PRIMARY PREVENTION; PRIORITY JOURNAL; SAMPLE SIZE; STROKE; UNITED STATES; WOMEN'S HEALTH;

EID: 84863445053     PISSN: 12797707     EISSN: 17604788     Source Type: Journal    
DOI: 10.1007/s12603-012-0011-6     Document Type: Article

References (29)

1. Plassman BL, Williams JW, Burke Jr, holsinger T, Benjamin S. Systematic review: Factors Associated With risk for and Possible Prevention of cognitive decline in Later Life. Annals of internal Medicine. August 3, 2010 2010;153 (3):182-193.
2. Daviglus ML, Bell CC, Berrettini W, et al. national institutes of health State-of-The-Science conference Statement: Preventing Alzheimer disease and cognitive decline. Annals of internal Medicine. August 3, 2010 2010;153 (3):176-181.
3. Mcclendon MJ, Hernandez S, Smyth KA, Lerner AJ. Memantine and Acetylcholinesterase inhibitor Treatment in cases of cdr 0.5 or Questionable impairment. Journal of Alzheimer's disease. 2009;16 (3):577-583.
4. Schneider LS, Insel PS, Weiner MW, For the Alzheimer's disease neuroimaging initiative. Treatment With cholinesterase inhibitors and memantine of patients in the Alzheimer's disease neuroimaging initiative. Archives of neurology. January 1, 2011 2011;68 (1):58-66.
5. Weinstein AM, Barton C, Ross L, Kramer Jh, Yaffe K. Treatment practices of mild cognitive impairment in california Alzheimer's disease centers. Journal of the American Geriatrics Society. 2009;57 (4):686-690.
6. Roberts JS, Karlawish JH, Uhlmann WR, Petersen RC, Green RC. Mild cognitive impairment in clinical care: A survey of American Academy of neurology members. Neurology. August 3, 2010 2010;75 (5):425-431.
7. Golde TE, Schneider LS, Koo EH. Anti-A? Therapeutics in Alzheimer's disease: The need for a Paradigm Shift. neuron. 2011;69 (2):203-213.
8. Schneider LS. Prevention therapeutics of dementia. Alzheimer's & dementia. Jan 2008;4 (1 Suppl 1):S122-130.
9. Thal LJ, Carta A, Doody R, et al. Prevention protocols for Alzheimer disease. Position paper from the international Working Group on harmonization of dementia drug Guidelines. Alzheimer dis Assoc disord. 1997;11 (Suppl 3):46-49. (Pubitemid 127726420)
10. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breastcancer prevention trials. The Lancet. 2003;361 (9354):296-300. (Pubitemid 36126189)
11. Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. Bmj. October 21, 2000 2000;321 (7267):983.
12. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi i, Tognoni G, Brown dL. Aspirin for the Primary Prevention of cardiovascular events in Women and Men. JAMA: The Journal of the American Medical Association. January 18, 2006 2006;295 (3):306-313.
13. Coley N, Andrieu S, Gardette V, et al. dementia Prevention: Methodological explanations for inconsistent results. epidemiologic reviews. november 1, 2008 2008;30 (1):35-66.
14. AdAPT Research Group. Naproxen and Celecoxib do not prevent Ad in early results from a randomized controlled trial. neurology. May 22, 2007 2007;68 (21):1800-1808.
15. Dekosky ST, Williamson JD, Fitzpatrick AL, et al. Ginkgo biloba for Prevention of dementia: A randomized controlled Trial. JAMA. november 19, 2008 2008;300 (19):2253-2262.
16. Andrieu S, Ousset P, Coley N, Ouzid M, Mathiex-Fortunet h, Vellas B. GuidAge Study: A 5- Year double Blind, randomised Trial of eGb 761 for the Prevention of Alzheimers disease in elderly Subjects with Memory complaints. i. rationale, design and Baseline data. current Alzheimer research. 2008;5:406-415.
17. Sano M, Jacobs D, Andrews H, et al. A multi-center, randomized, double blind placebocontrolled trial of estrogens to prevent Alzheimer's disease and loss of memory in women: design and baseline characteristics. clin. 2008;5 (5):523-533.
18. Shumaker SA, Legault C, Kuller L, et al. conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's health initiative Memory Study.[see comment]. JAMA. 2004;291 (24):2947-2958. (Pubitemid 38802684)
19. Shumaker SA, Legault C, Rapp SR, et al. estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's health initiative Memory Study: a randomized controlled trial.[see comment]. JAMA. 2003;289 (20):2651-2662. (Pubitemid 37430136)
20. Mrc/BhF heart Protection Study of cholesterol lowering with simvastatin in 20[punctuation space]536 high-risk individuals: a randomised placebocontrolled trial. The Lancet. 2002;360 (9326):7-22.
21. Kryscio R.J. Mendiondo M.S. Schmitt F.A. Markesbery W.R., Designing a large prevention trial: Statistical issues, Statistics in Medicine, 2004, 23, 2, 285-296 (Pubitemid 38100641)
22. Kryscio RJ, Mendiondo MS, Schmitt FA, Markesbery WR. designing a large prevention trial: statistical issues. Statistics in Medicine. 2004;23 (2):285-296. 22. Kivipelto M, helkala e-L, Laakso MP, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. Bmj. June 16, 2001 2001;322 (7300):1447-1451. (Pubitemid 32575406)
23. Andrieu S, Coley N, Aisen P, et al. Methodological issues in Primary Prevention Trials for neurodegenerative dementia. Journal of Alzheimer's disease. 2009;16 (2):235-270.
24. Schneider LS, Kennedy RE, Cutter GR. Requiring an amyloid-[beta]1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimer's and dementia. 2010;6 (5):367-377.
25. Reiman EM, Langbaum JB, Tariot PN. Alzheimer's Prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. Biomarkers in Medicine. 2010;4 (1):3-14.
26. Acosta-Baena N, Sepulveda-Falla D, Lopera-Gómez CM, et al. Pre-dementia clinical stages in presenilin 1 e280A familial early-onset Alzheimer's disease: a retrospective cohort study. The Lancet neurology. 2011;10 (3):213-220.
27. Maitournam A, Simon R. On the efficiency of targeted clinical trials. Statistics in Medicine. 2005;24 (3):329-339. (Pubitemid 40227650)
28. Khachaturian ZS, Snyder PJ, Doody R, et al. A roadmap for the prevention of dementia ii: Leon Thal Symposium 2008.[see comment]. Alzheimer's & dementia. Mar 2009;5 (2):85-92.
29. Schneider LS. corporation for cognitive impairment. Alzheimer's & dementia. 2009;5